Torrent Pharmaceuticals Stock Price - ₹4,905.50 | Healthcare

‌
‌
‌

Company insights, generated from the most recent coverage.

Q1 FY27 net profit grew only 3% YoY despite 55% revenue growth, causing net margin to compress from 17.45% to 11.53%.
Germany revenues down 9% in constant currency due to third-party supply disruption and lower tender offtake.
Trading at 87x PE and 9.6x PB, the stock is highly sensitive to earnings disappointments given its rich valuation.

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Torrent Pharma shows steady revenue growth and expanding margins, driven by strong India performance and a healthy international pipeline.

Consolidated revenue grows from ₹3,178 Cr in Q1 FY26 to ₹4,921 Cr in Q1 FY27 — strong volume recovery drives top-line expansion

Brazil revenue falls from ₹907 Cr in Q3 FY26 to ₹455 Cr in Q4 FY26 — post-peak normalization reduces short-term gains

India revenue rises from ₹1,811 Cr in Q1 FY26 to ₹2,890 Cr in Q1 FY27 — steady domestic demand supports consistent growth

US revenue drops from ₹967 Cr in Q3 FY26 to ₹396 Cr in Q4 FY26 — seasonal demand normalization impacts quarterly output

Germany revenue surges from ₹308 Cr in Q1 FY26 to ₹916 Cr in Q3 FY26 — successful market penetration boosts European sales

Others revenue declines from ₹1,563 Cr in Q3 FY26 to ₹112 Cr in Q4 FY26 — volatile non-core streams require closer monitoring

‌
‌
‌

In the news

Torrent Pharma shares rise 2.02% to ₹4,999 on strong Q1 performance

Morgan Stanley upgrades Torrent Pharma, downgrades Mankind

Torrent Pharma gets Neutral rating, target Rs 4730: Motilal Oswal

Torrent, Mankind Pharma Report Strong Q1 Growth on Domestic Demand

Torrent Pharma shares rise 2.18% on strong Q4 results

Torrent Pharmaceuticals shares fall 2.91% despite strong growth

Torrent Pharma, RBL Bank Face MSCI Index Changes on July 16

India's Fat-Loss Drug Market Cooling as Generics Disrupt Premium Imports

Dr Reddy's shares crash 9% in 2 days; brokerages slash target prices

Torrent Pharmaceuticals drops 5th straight session, down 0.36%

Prabhudas Lilladher maintains Rs 5000 target for Torrent Pharma

Torrent Pharma surges 3.06% for third straight session

Pharma stocks surge 9% in 2026 with brokerage upside targets

Torrent Pharma hits 52-week high on Q4 results, brokerages see upside

Torrent Pharma Q4 Results Beat Estimates; Nirmal Bang Maintains Hold

Stocks to Watch Today: NTPC, Eicher Motors, Paytm Lead Q4 Results

Torrent Pharma Q4 profit drops 22% to ₹389 cr on JB Pharma costs

Torrent Pharma Q4 profit drops 21.9% due to acquisition costs

Torrent Pharma Q3 profit surges 26% to ₹635 crore, shares hit record high

Torrent Pharmaceuticals shares rise 2.03%, top Nifty Next 50 gainer

Torrent Pharmaceuticals